Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILe: Spinal morphine or intravenous lidocaine in robot-assisted upper urologic surgery
2023-505941-21-00Phase 3Authorised
- Sponsor
- Region Östergötland
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of morphine, lidocaine and bupivacaine in kidney cancer, ureteral cancer, benign kidney neoplasm and 3 more (2 arms), sponsored by Region Östergötland. Primary endpoint: QoR-15 score at postoperative day 1. Planned start Oct 2023; status: authorised.
02
Drugs
morphinelidocainebupivacaine
03
Conditions
kidney cancerureteral cancerbenign kidney neoplasmbenign ureteral neoplasmnephrolithiasis
Beyond the preview
Go deeper on 2023-505941-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505941-21-00.